Why the study?
Does rivastigmine tartrate improve cognitive and clinical outcomes in patients with mild to moderately severe Alzheimer's disease with or without concurrent vascular risk factors?
Population
699 patients with mild to moderately severe Alzheimer's disease with or without concurrent vascular risk…
Comparison
Rivastigmine tartrate for 26 weeks vs Placebo for 26 weeks
Design
RCT, randomized
Follow-up
26 weeks
Authors
Loading...
High-dose rivastigmine improves cognition in mild-moderate Alzheimer's regardless of vascular risk; extends benefit to mixed-histopathology subgroups.
Does rivastigmine tartrate improve cognitive and clinical outcomes in patients with mild to moderately severe Alzheimer's disease with or without concurrent vascular risk factors?
Rivastigmine is effective in treating mild to moderately severe Alzheimer's disease, with greater clinical benefit observed in patients with concurrent vascular risk factors.
Kumar et al. (2000) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: